摘要:
The present invention is directed to a novel pharmaceutical formulation comprising 3α-ethynyl-3β-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepatic encephalopathy by the use of a pharmaceutical formulation as claimed.
摘要:
The present invention is directed to a novel pharmaceutical formulation comprising 3α-ethynyl-3β-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepatic encephalopathy by the use of a pharmaceutical formulation as claimed.
摘要:
The present invention provides the steroidal compound 3□-ethynyl-3□-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
摘要:
The present invention is directed to a method for the treatment of cognitive impairment in a cirrhotic patient with hepatic encephalopathy (HE), said patient having a CRT index (continous reaction time index) below 1.9 at baseline (prior to treatment), whereby the compound golexanolone (3α-ethynyl-3β-hydroxyandrostan-17-one oxime) of formula (I) or a pharmaceutically acceptable salt thereof, is administered to said patient.
摘要:
The present invention is directed to a novel pharmaceutical formulation comprising 3α-ethynyl-3β-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepathic encephalopathy by the use of a pharmaceutical formulation as claimed.
摘要:
The present invention provides the steroidal compound 3α-ethynyl-3β-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
摘要:
The present invention provides the steroidal compound 3□-ethynyl-3□-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
摘要:
There is provided a method of treatment of hypersomnolence comprising administering the steroidal compound 3α-ethynyl-3β-hydroxy-5α-androstan-17-one oxime, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment.
摘要:
The present invention provides the steroidal compound 3α-ethynyl-3β-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
摘要:
There is provided a method of treatment of hypersomnolence comprising administering the steroidal compound 3α-ethynyl-3β-hydroxy-5α-androstan-17-one oxime, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment.